Myriad Genetics Files 8-K

TL;DR

MYGN filed an 8-K, standard disclosure, nothing major to see here.

AI Summary

Myriad Genetics, Inc. filed an 8-K on November 26, 2024, to report current information as required by the SEC. The filing indicates the company's principal executive offices are located at 322 North 2200 West, Salt Lake City, Utah, 84116. This report is filed under the 1934 Act and pertains to Regulation FD Disclosure and Financial Statements and Exhibits.

Why It Matters

This filing is a standard regulatory disclosure, indicating Myriad Genetics is meeting its SEC reporting obligations. It confirms the company's operational address and filing status.

Risk Assessment

Risk Level: low — This is a routine regulatory filing and does not contain new material information that would typically impact stock price or risk.

Key Players & Entities

• MYRIAD GENETICS, INC. (company) — Registrant
• November 26, 2024 (date) — Date of earliest event reported
• 322 North 2200 West, Salt Lake City, Utah, 84116 (location) — Address of principal executive offices
• 0-26642 (other) — Commission File Number
• 87-0494517 (other) — IRS Employer Identification No.

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value MYGN Nasdaq Global Select Mar
• $950,000 — orneys' fees and expenses not to exceed $950,000 to be paid by the Company, and that the

Filing Documents

• mygn-20241126.htm (8-K) — 32KB
• 0000899923-24-000060.txt ( ) — 179KB
• mygn-20241126.xsd (EX-101.SCH) — 2KB
• mygn-20241126_def.xml (EX-101.DEF) — 14KB
• mygn-20241126_lab.xml (EX-101.LAB) — 25KB
• mygn-20241126_pre.xml (EX-101.PRE) — 15KB
• mygn-20241126_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

ITEM 7.01 Regulation FD Disclosure. As previously disclosed, beginning on August 9, 2021, two purported shareholder derivative complaints were filed with the Court of Chancery of the State of Delaware (the " Court ") against Myriad Genetics, Inc. (the " Company "), as nominal defendant, and certain of the Company's current and/or former directors and officers. On March 3, 2022, the cases were consolidated under the caption In re Myriad Genetics, Inc. Stockholder Derivative Litigation , Case No. 2021-0686-SG (the " Derivative Action "). During the same period, a purported stockholder derivative complaint against the Company and certain current and/or former directors and officers of the Company was filed with the United States District Court for the District of Delaware, captioned Marcey v. Capone, et al. , Case No. 1:21-cv-01320-MN (D. Del.) (the " Federal Derivative Action ", and together with the Derivative Action, the " Derivative Litigation "). The complaints generally allege that certain current and/or former directors and officers of the Company breached their fiduciary duties to the Company and engaged in other wrongdoings. On April 30, 2024, the parties agreed to settle the Derivative Litigation pursuant to a global stipulation of settlement (the " Settlement "). As part of the Settlement, (i) the Company agreed to adopt or implement certain corporate governance reforms; and (ii) the parties agreed that plaintiffs' counsel will apply to the Court for an award of attorneys' fees and expenses not to exceed $950,000 to be paid by the Company, and that the individual defendants and the Company will not oppose or object to the requested fee award. The Settlement contains no admission of liability, wrongdoing or responsibility by any of the parties. On May 3, 2024, the parties submitted the Settlement to the Court for approval. On August 6, 2024, the Court held a hearing to consider the Settlement. On November 26, 2024, the Settlement was approved by the Cou

01 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MYRIAD GENETICS, INC. Date: November 26, 2024 By: /s/ Scott J. Leffler Scott J. Leffler Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR